bf/NYSE:ABBV_icon.jpeg

NYSE:ABBV

AbbVie Inc.

  • Stock

USD

Last Close

180.35

28/03 20:00

Market Cap

290.25B

Beta: 0.55

Volume Today

3.08M

Avg: 6.07M

PE Ratio

46.58

PFCF: 12.27

Dividend Yield

3.48%

Payout:159.95%

  • industry

    Drug Manufacturers / General
  • exchange

    New York Stock Exchange
  • website

    www.abbvie.com
  • ipo date

    Jan 02, 2013
  • full time employees

    50,000
  • currency

    USD

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for th...Show More

Earnings

Earnings per Share (Estimate*)

12342015-07-242017-07-282019-07-262021-07-302023-07-27

Revenue (Estimate*)

5B10B15B2015-07-242017-07-282019-07-262021-07-302023-07-27

*Estimate based on analyst consensus

founders

  • S Nikhil Kumar

investments

Money RaisedFunding RoundLead InvestorAnnounced DateOrganization Name
Corporate Round - CapsidaYes23-02-2023Capsida
$30MSeries C - Carisma Therapeutics21-09-2022Carisma Therapeutics
Grant - The Institute for Family Health31-08-2021The Institute for Family Health
Grant - The Night Ministry31-08-2021The Night Ministry
Grant - Health Brigade31-08-2021Health Brigade
Grant - MLK Health Center31-08-2021MLK Health Center
Grant - Delaware Valley Community Health31-08-2021Delaware Valley Community Health
Grant - Roanoke Chowan Community Health Center31-08-2021Roanoke Chowan Community Health Center
Grant - Eskenazi Health31-08-2021Eskenazi Health
Grant - Good Samaritan Health Center31-08-2021Good Samaritan Health Center

acquisitions

PriceAcquiree NameAnnounced DateTransaction Name
ImmunoGen30-11-2023ImmunoGen acquired by AbbVie
$255MDJS Antibodies20-10-2022DJS Antibodies acquired by AbbVie
$1BSyndesi Therapeutics01-03-2022Syndesi Therapeutics acquired by AbbVie
Mitokinin10-03-2021Mitokinin acquired by AbbVie
Mavupharma15-07-2019Mavupharma acquired by AbbVie
$63BAllergan25-06-2019Allergan acquired by AbbVie
$5.8BStemcentrx28-04-2016Stemcentrx acquired by AbbVie
$21BPharmacyclics04-03-2015Pharmacyclics acquired by AbbVie
ImmuVen01-01-2014ImmuVen acquired by AbbVie

num employees

  • 10001+

funding rounds

Money RaisedAnnounced DateLead InvestorsTransaction NameNumber of Investors
$15B27-02-2024Post-IPO Debt - AbbVie
$250K08-03-2023Post-IPO Equity - AbbVie

Please Sign In To Use The Chat

The chat is only available for registered users, please sign in or create your free account.